Fennec Pharmaceuticals Announces Common Share Offering
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) has successfully concluded the pricing of an underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. This move is part of a strategic initiative to enhance its financial position and support expansion plans.
Details of the Offering
The offering also includes an option for underwriters to purchase an additional 700,000 common shares within a span of 30 days. The anticipated total gross proceeds from the offering, before any deductions related to underwriting discounts and expenses, are projected to be around $35,000,000, though this amount may vary depending on the eventual exercise of the over-allotment option.
Use of Proceeds
Fennec intends to allocate the net proceeds from this offering towards repaying certain debts while reserving any remaining funds for working capital and general corporate needs. This approach reflects the company's commitment to maintaining financial health as it continues to execute its growth strategies.
Management of the Offering
The offering will be managed by several key financial institutions. Piper Sandler & Co. and Craig-Hallum Capital Group LLC will act as the joint book-running managers, with H.C. Wainwright & Co. serving as lead manager, and Stephens Inc. as co-manager. This assemblage of firms showcases the confidence the financial community has in Fennec's potential.
Regulatory Compliance and Availability of Documents
The common shares are being offered pursuant to a registration statement that has been approved by the Securities and Exchange Commission (SEC). Fennec will file a final prospectus supplement and accompanying prospectus with the SEC, which will be accessible on their website.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is dedicated to combating ototoxicity caused by cisplatin-based chemotherapy in cancer patients. A major focus of the company is the commercialization of PEDMARK to mitigate platinum-induced ototoxicity. The product has received crucial approvals recently, including from the FDA and European Commission, which makes it an important aspect of Fennec's growth trajectory.
Recent Developments
In a notable strategic move, Fennec has partnered with Norgine Pharmaceuticals Ltd. for exclusive rights to market PEDMARQSI in specified regions including Europe and the U.K. This partnership will enhance availability and accessibility of the treatment across these territories, representing a significant step forward for the company.
Market Position and Future Prospects
With PEDMARK granted Orphan Drug Exclusivity in the U.S. and PEDMARQSI securing Pediatric Use Marketing Authorization in Europe, Fennec has firmly established itself in the pharmaceutical landscape. The company is building on its intellectual property with patents that protect PEDMARK until 2039, ensuring a robust market presence and competitive edge.
Frequently Asked Questions
What is the purpose of Fennec Pharmaceuticals' new offering?
The offering aims to bolster Fennec's financial resources through the sale of common shares to support debt repayment and fund corporate initiatives.
When is the anticipated closing date for the offering?
The offering is expected to close shortly, subject to standard closing conditions.
How has Fennec Pharmaceuticals positioned itself in the market?
Fennec is recognized for its innovative solutions focusing on reducing cancer treatment side effects, particularly through its product PEDMARK.
Who are the financial partners involved in this offering?
Piper Sandler, Craig-Hallum Capital Group LLC, H.C. Wainwright, and Stephens Inc. are key financial institutions coordinating this offering.
What are the recent approvals received by Fennec's products?
PEDMARK has received FDA approval, along with additional endorsements from the European Commission and the U.K., highlighting its potential in the market.
